RADAR Trial - Randomised Androgen Deprivation and Radiotherapy
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
The principal objectives of the RADAR trial is to address the hypotheses; 1) that 18 months
androgen deprivation in conjunction with radiotherapy is superior to 6 months androgen
deprivation prior to and during radiotherapy; 2) that 18 months Bisphosphonate therapy will
prevent bone loss caused by androgen deprivation therapy and further reduce relapse risk by
impeding the development of bony metastases.
Phase:
Phase 3
Details
Lead Sponsor:
Trans Tasman Radiation Oncology Group Trans-Tasman Radiation Oncology Group (TROG)
Collaborators:
Abbott Calvary Mater Newcastle, Australia Cancer Society of New Zealand Health Research Council, New Zealand Hunter Medical Research Institute (HMRI) Maitland Cancer Appeal National Health and Medical Research Council, Australia Novartis Pharmaceuticals University of Newcastle, Australia